{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:55:50Z","timestamp":1791816950644,"version":"4.3.4"},"reference-count":29,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite advances in anticoagulant therapy, thrombosis remains the leading cause of morbidity and mortality worldwide. Heparin and vitamin K antagonists (VKAs), the first anticoagulants to be used successfully for the prevention and treatment of thrombosis, are associated with a risk of bleeding. These agents target multiple coagulation factors. Thus, by activating antithrombin, heparin mainly inhibits factor Xa and thrombin, whereas VKAs lower the levels of the vitamin K\u2013dependent clotting factors. Direct oral anticoagulants, which have replaced VKAs for many indications, inhibit only factor Xa or thrombin. Although the direct oral anticoagulants are associated with less bleeding than VKAs, bleeding remains their major side effect. Epidemiological and animal studies have identified factor XI as a target for potentially safer anticoagulant drugs because factor XI deficiency or inhibition protects against thrombosis and is associated with little or no bleeding. Several factor XI\u2013directed strategies are currently under investigation. This article (1) reviews the rationale for the development of factor XI inhibitors, (2) identifies the agents in most advanced stages of development, (3) describes the results of completed clinical trials and provides a summary of those underway, and (4) highlights the opportunities and challenges for this next generation of anticoagulants.<\/jats:p>","DOI":"10.1055\/a-1384-3715","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T05:36:00Z","timestamp":1618551360000},"page":"104-110","source":"Crossref","is-referenced-by-count":81,"title":["Factor XI as a Target for New Anticoagulants"],"prefix":"10.1055","volume":"41","author":[{"given":"James C.","family":"Fredenburgh","sequence":"additional","affiliation":[{"name":"Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada"},{"name":"Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[{"name":"Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada"},{"name":"Department of Medicine, McMaster University, Hamilton, Ontario, Canada"},{"name":"Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2019.10.023","article-title":"Fifty years of research on antithrombotic therapy: achievements and disappointments","volume":"70","author":"J Hirsh","year":"2019","journal-title":"Eur J Intern Med"},{"issue":"07","key":"ref2","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1160\/TH16-10-0807","article-title":"New developments in anticoagulants: past, present and future","volume":"117","author":"J I Weitz","year":"2017","journal-title":"Thromb Haemost"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"C T Ruff","year":"2014","journal-title":"Lancet"},{"issue":"06","key":"ref4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.blre.2018.04.001","article-title":"Plasma contact factors as therapeutic targets","volume":"32","author":"B F Tillman","year":"2018","journal-title":"Blood Rev"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/ATVBAHA.118.312130","article-title":"Intrinsic pathway of coagulation and thrombosis","volume":"39","author":"S P Grover","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1126\/science.1652157","article-title":"Factor XI activation in a revised model of blood coagulation","volume":"253","author":"D Gailani","year":"1991","journal-title":"Science"},{"issue":"04","key":"ref7","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/CIRCRESAHA.119.314581","article-title":"Extracellular DNA NET-Works with dire consequences for health","volume":"125","author":"N Sorvillo","year":"2019","journal-title":"Circ Res"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/rth2.12162","article-title":"Polyphosphate in thrombosis, hemostasis, and inflammation","volume":"3","author":"C J Baker","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"05","key":"ref9","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/jth.13209","article-title":"The Alzheimer's disease peptide \u03b2-amyloid promotes thrombin generation through activation of coagulation factor XII","volume":"14","author":"D Zamolodchikov","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1160\/TH17-07-0492","article-title":"Atherothrombosis and thromboembolism: Position paper from the second Maastricht Consensus Conference on Thrombosis","volume":"118","author":"H MH Spronk","year":"2018","journal-title":"Thromb Haemost"},{"issue":"09","key":"ref11","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"M Preis","year":"2017","journal-title":"Blood"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1161\/STROKEAHA.119.026545","article-title":"Leveraging human genetics to estimate clinical risk reductions achievable by inhibiting factor XI","volume":"50","author":"B Georgi","year":"2019","journal-title":"Stroke"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1309\/QC259F09UNMKVP0R","article-title":"Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events","volume":"126","author":"D T Yang","year":"2006","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"ref14","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1056\/NEJM200003093421004","article-title":"High levels of coagulation factor XI as a risk factor for venous thrombosis","volume":"342","author":"J C Meijers","year":"2000","journal-title":"N Engl J Med"},{"issue":"06","key":"ref15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1055\/s-0033-1353420","article-title":"Congenital factor XI deficiency: an update","volume":"39","author":"S Duga","year":"2013","journal-title":"Semin Thromb Hemost"},{"issue":"22","key":"ref16","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2010-04-277798","article-title":"Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk","volume":"116","author":"H Zhang","year":"2010","journal-title":"Blood"},{"issue":"13","key":"ref17","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood-2013-12-540872","article-title":"Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits","volume":"123","author":"J W Yau","year":"2014","journal-title":"Blood"},{"issue":"02","key":"ref18","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/ATVBAHA.117.309664","article-title":"2017 Scientific Sessions Sol Sherry Distinguished Lecture in Thrombosis: Factor XI as a target for new anticoagulants","volume":"38","author":"J I Weitz","year":"2018","journal-title":"Arterioscl Thromb Vasc Biol"},{"issue":"02","key":"ref19","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/jth.12797","article-title":"Fasxiator, a novel factor XIa inhibitor from snake venom, and its site-specific mutagenesis to improve potency and selectivity","volume":"13","author":"W Chen","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1084\/jem.20091007","article-title":"Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis","volume":"206","author":"Y Decrem","year":"2009","journal-title":"J Exp Med"},{"issue":"02","key":"ref21","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/jth.15130","article-title":"Dual inhibition of factor XIIa and factor XIa as a therapeutic approach for safe thromboprotection","volume":"19","author":"S Demoulin","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref22","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/MOH.0000000000000452","article-title":"Emerging applications of aptamers for anticoagulation and hemostasis","volume":"25","author":"C V Chabata","year":"2018","journal-title":"Curr Opin Hematol"},{"issue":"05","key":"ref23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41573-020-0061-0","article-title":"Therapeutic strategies for thrombosis: new targets and approaches","volume":"19","author":"N Mackman","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"03","key":"ref24","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"H R B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"key":"ref25","first-page":"1116","article-title":"Pharmacokinetics and pharmacodynamics of Ionis-FXIRx, an antisense inhibitor of factor XI, in patients with end-stage renal disease on hemodialysis","volume":"130","author":"C Bethune","year":"2017","journal-title":"Blood"},{"issue":"02","key":"ref26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"J I Weitz","year":"2020","journal-title":"JAMA"},{"issue":"13","key":"ref27","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans","volume":"133","author":"A W Koch","year":"2019","journal-title":"Blood"},{"issue":"04","key":"ref28","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/ATVBAHA.118.312328","article-title":"Contact activation inhibitor and factor XI antibody, AB023, produces safe, dose-dependent anticoagulation in a phase 1 first-in-human trial","volume":"39","author":"C U Lorentz","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"03","key":"ref32","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1182\/blood-2003-01-0324","article-title":"Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates","volume":"102","author":"A Gruber","year":"2003","journal-title":"Blood"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1384-3715.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T05:36:37Z","timestamp":1618551397000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1384-3715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":29,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2021,4,15]]},"published-print":{"date-parts":[[2021,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1384-3715","relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}